71 related articles for article (PubMed ID: 22064107)
1. Lack of concordance between the F-18 fluoromisonidazole PET and the F-18 FDG PET in human glioblastoma.
De Clermont H; Huchet A; Lamare F; Rivière A; Fernandez P
Clin Nucl Med; 2011 Dec; 36(12):e194-5. PubMed ID: 22064107
[No Abstract] [Full Text] [Related]
2. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of
Okamoto M; Yamaguchi S; Sawaya R; Echizenya S; Ishi Y; Kaneko S; Motegi H; Toyonaga T; Hirata K; Fujimura M
Biomed Res Int; 2024; 2024():2973407. PubMed ID: 38449509
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
4. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
5. Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports.
Narita T; Aoyama H; Hirata K; Onodera S; Shiga T; Kobayashi H; Murata J; Terasaka S; Tanaka S; Houkin K
Jpn J Clin Oncol; 2012 Feb; 42(2):120-3. PubMed ID: 22198964
[TBL] [Abstract][Full Text] [Related]
6. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
7. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure.
Douglas JG; Stelzer KJ; Mankoff DA; Tralins KS; Krohn KA; Muzi M; Silbergeld DL; Rostomily RC; Scharnhorst J; Spence AM
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):886-91. PubMed ID: 16242251
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104
[TBL] [Abstract][Full Text] [Related]
9. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole.
Valk PE; Mathis CA; Prados MD; Gilbert JC; Budinger TF
J Nucl Med; 1992 Dec; 33(12):2133-7. PubMed ID: 1334136
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of newly diagnosed glioblastoma multiforme and intracranial diffuse large B-cell Lymphoma using (11)C-methionine and (18)F-FDG PET.
Okada Y; Nihashi T; Fujii M; Kato K; Okochi Y; Ando Y; Yamashita M; Maesawa S; Takebayashi S; Wakabayashi T; Naganawa S
Clin Nucl Med; 2012 Sep; 37(9):843-9. PubMed ID: 22889772
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution, pharmacokinetics and PET imaging of [(18)F]FMISO, [(18)F]FDG and [(18)F]FAc in a sarcoma- and inflammation-bearing mouse model.
Liu RS; Chou TK; Chang CH; Wu CY; Chang CW; Chang TJ; Wang SJ; Lin WJ; Wang HE
Nucl Med Biol; 2009 Apr; 36(3):305-12. PubMed ID: 19324276
[TBL] [Abstract][Full Text] [Related]
13. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
Tralins KS; Douglas JG; Stelzer KJ; Mankoff DA; Silbergeld DL; Rostomily RC; Hummel S; Scharnhorst J; Krohn KA; Spence AM
J Nucl Med; 2002 Dec; 43(12):1667-73. PubMed ID: 12468518
[TBL] [Abstract][Full Text] [Related]
14. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
[TBL] [Abstract][Full Text] [Related]
15. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.
Segard T; Robins PD; Yusoff IF; Ee H; Morandeau L; Campbell EM; Francis RJ
Clin Nucl Med; 2013 Jan; 38(1):1-6. PubMed ID: 23242037
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
[TBL] [Abstract][Full Text] [Related]
17. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.
Gagel B; Reinartz P; Dimartino E; Zimny M; Pinkawa M; Maneschi P; Stanzel S; Hamacher K; Coenen HH; Westhofen M; Büll U; Eble MJ
Strahlenther Onkol; 2004 Oct; 180(10):616-22. PubMed ID: 15480509
[TBL] [Abstract][Full Text] [Related]
18. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
Bruehlmeier M; Roelcke U; Schubiger PA; Ametamey SM
J Nucl Med; 2004 Nov; 45(11):1851-9. PubMed ID: 15534054
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer.
Denholt CL; Binderup T; Stockhausen MT; Poulsen HS; Spang-Thomsen M; Hansen PR; Gillings N; Kjær A
Nucl Med Biol; 2011 May; 38(4):509-15. PubMed ID: 21531288
[TBL] [Abstract][Full Text] [Related]
20. Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog.
Shibahara I; Kumabe T; Kanamori M; Saito R; Sonoda Y; Watanabe M; Iwata R; Higano S; Takanami K; Takai Y; Tominaga T
J Neurosurg; 2010 Aug; 113(2):358-68. PubMed ID: 19895196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]